We studied the effects of long-term suppressive thyroxine treatment on serum markers of bone collagen synthesis and degradation in thyroid carcinoma patients, and the relationship of these effects to the serum concentrations of thyrotropin, free thyroxine and free triiodothyronine were investigated. Thirty-seven thyroid carcinoma patients receiving a stable thyroxine dose, and thirty-five controls participated in a cross-sectional study. Bone collagen synthesis and degradation were measured by using specific radioimmunoassays to determine the serum concentrations of carboxyterminal propeptide of type I procollagen, and carboxyterminal telopeptide region of type I collagen, respectively. Serum thyrotropin, free T 4 and free T 3 were measured by timeresolved fluoroimmunoassays (Delfia®). Serum carboxyterminal telopeptide region of type I collagen concentrations of thyroid carcinoma patients were significantly higher than those of the controls (p = 0.0012). Serum carboxyterminal propeptide of type I procollagen concentrations did not differ significantly between the patients and controls (p = 0.85). Significant associations between age or physical activity, and carboxyterminal propeptide of type I procollagen or carboxyterminal telopeptide region of type I collagen were found in the controls, but not in the patients. Thyrotropin, free T 4 or free T 3 were not significantly associated with carboxyterminal propeptide of type I procollagen or carboxyterminal telopeptide region of type I collagen in either the control or patient group.
Introduction
suppression, however, remains uncertain (l). Long-term suppressive thyroxine treatment may cause side effects Patients with thyroid carcinoma need postoperative thy-such a$ an increased risk of os teoporosis (2, 3) . Convenroxine Substitution. The optimal degree of thyrotropin tional , methods for stu dyin g bone metabolism and osteo-_ porosis include measurements of bone mineral density.
K
These methods are expensive, sometimes laborious, and utüi» radiation. Biochemica. markers for bone metabodonated froin Orion Diagnostica, Turku, Finland.
lism have also been used, such äs urinary hydroxypro-line, pyridinoline and deoxypyridinoline cross-links. However, if urinary hydroxyproline is used äs an index, the subject must receive a special diet. New techniques have been developed for the measurement of specific indicators of bone metabolism in a single serum sample. Type I collagen accounts for 90 percent of the organic matrix of bone. Carboxyterminal propeptide of type I procollagen is an indicator of type I collagen synthesis in the body, and carboxyterminal telopeptide parts of type I collagen are a corresponding indicator of the degradation of type I collagen. These new serum markers have made it possible to measure bone metabolism easily (4, 5) .
The aims of the present study were to examine:
1) whether long-term thyroxine treatment for the suppression of thyrotropin secretion has effects on biochemical markers of bone metabolism in thyroid cancer patients;
2) the value of thyrotropin, free thyroxine, and free triiodothyronine in the prediction of the possible alterations in bone metabolism.
Materials and Methods

Subjects
Thirty-seven patients who had undergone a primary radical Operation for differentiated papillary or follicular thyroid carcinoma, and thirty-five controls participated in the study. All patients received long-term suppressive thyroxine treatment. Subject characteristics are presented in table 1. The procedures followed were in accordance with the Helsinki Declaration of 1975, äs revised in 1983.
Laboratory methods
Bone collagen synthesis and degradation were determined by measuring the serum concentrations of carboxyterminal propeptide of type I procollagen, and carboxyterminal telopeptide region of type I collagen, respectively (Orion Diagnostica, Finland), using specific radioirnmunoassays (4, 6) . Carboxyterminal propeptide of type I procollagen is a trimeric, globular protein that is cleaved off from type I collagen molecules beföre the latter are assembled into fibers. This cleavage must be complete to ensure correct fibril and fiber formation. Thus the amount of cärboxyterminal propeptide of type I procollagen released is directly related to the number of collagen molecules forrned, and the assay of carboxyterminal propeptide of type I procollagen can be used to quantify type I collagen synthesis in the body. Carboxyterminal telopeptide region of type l collagen is a cross-linked telopeptide frorri type I collagen fibres. It i s liberated duririg the degradation of type I collagen, and the carboxyterminal telopeptide region of type I collagen assay can be used to quantify type l collagen degfadation in the body. Serum thyrotropin was measured with a third-generation assay based on time-resolved fluorescence (Delfia® hTSH Ultra, Wallac, Finland) with a reference interval of 0.5-4.7 mlU/1 established by our own laboratory. The functional sensitivity of the thyrotropin method was 0.005 mIU/1 (20% betweenrassay CV) (7). Serum free T 4 and free T 3 were also measured with time-resolved fluoroimmunoassays (Delfia). Reference intervals for free T 4 and free T 3 were 7.6-19.7 pmol/1 (according to rnanufacturer) and 4.2-7.6 pmol/1 (establ ished by our own laboratory).
Physical activity index
Participation in leisure^time physical activity was assessed by using a questionnaire. The subjects were asked the frequency of participation in physical activity and the average intensity and duration of exercise. A sum index for physical activity was calculated from the product of intensity X duration X monthly frequency (8, 9 T 4 and free T 3 are presented äs medians, and non-parametric analyses (Mann-Whitney U-test) were used in the statistical computations, bccause the distribution was highly skewed. According to sex and menopausal Status, the subjects were classified into males, premenopausal females, and postmenopausal females. Carboxyterminal telopeptide region of type I Collagen and carboxyterminal propeptide of type I procollagen were examined between patients and controls (group) using an analysis of variance (group, menopausal Status) and covariance (age, physical activity index), No significant group by menopause interaction was found.
The relations of carboxyterminal telopeptide region of type I collagen and carboxyterminal propeptide of type I procol lagen to thyrotropin, free T 4 , free T 3 , age and physical activity were examined using linear regression analyses stratified by patient and control groups. Analyses were performed using version 6.04 of the Statistical Analysis System (SAS) scientific Software for microcomputers, and confidence intervals were calculated using the CIA (Confidence Interval Analysis) Software (10).
age + 92.96; R 2 = 41%). Also, age was significantly ,related to bone degradation (log carboxyterminal telopeptide region of type I collagen = 1.73 -0.014 X age; R 2 = 31%) in the controls. In contrast, no significant associations between age or physical activity, and carboxyterminal propeptide of type I procollagen or carboxyterminal telopeptide region of type I collagen were found in the patients. Figure l shows the effect of age on serum markers of bone formation and degradation in the patients and the controls. Thyrotropin, free T 4 or free T 3 were not significantly associated with carboxyterminal propeptide of type I procollagen or carboxyterminal telopeptide region of type I collagen within either the control or patient group in the linear regression analyses. Table 2 shows serum carboxyterminal propeptide of type I procollagen and carboxyterminal telopeptide region of type I collagen concentrations in the controls and patients. Mean serum carboxyterminal telopeptide region of type I collagen concentrations in thyroid carcinoma patients were higher than in controls (p = 0.0012). Mean serum carboxyterminal propeptide of type I procollagen concentrations did not differ significantly between patients and controls (p = 0.85). No significant differences were found between genders and menopausal groups. Age and physical activity were included äs covariates in the analyses.
Results
In the control group, linear regression analyses revealed that age and physical activity were significantly related to bone formation (carboxyterminal propeptide of type I procollagen = 0.29 X physical activity index -0.82 X Tab 
Discussion
The present study confirmed the finding that the ratio of bone resorption to bone formation is altered in states with high thyroid hormone concentrations. Many studies have shown that thyrotropin suppression caused by high doses of thyroid hormones decreases bone mass (11 -14) . Recently, it was also shown that thyroxine treatment with lower doses, in order to keep thyrotropin in reference interval, has only minor effect, if any, on bone mass (15, 16) . In these studies, bone mass and metabolism were studied by measurement of bone mineral density and biochemical markers of bone formation and resorption, such äs serum alkaline phosphatase, osteocalcin, urinary hydroxyproline, and urinary pyridinium crosslinks. The advantage of the new serum bone markers used in the present study, carboxyterminal propeptide of type I procollagen and carboxyterminal telopeptide region of type I collagen, lies in their high specificity for type I collagen which represents 90% of the organic bone rhatrix. These radioimmunoassays are easy to perform, and both measurements correlate well with bone mass according to histomorphometric studies (17) . Bone mineral density or content cannot be defmed by any biochemical marker. However, carboxyterminal propeptide of type I procollagen and carboxyterminal telopeptide region of type I collagen can be used äs indicators of bone turaover. Factors affecting the elimination of carboxyterminal propeptide of type I procollagen and carboxyterminal telopeptide region of type I collagen, e. g. increased glomerular filtration, were not studied in the present work.
In the present study, age and physical activity were significantly related to a serum marker of bone formation, and age to a serum marker of bone degradation in the controls. This is in agreement with previous studies (18) . No such associations were found in the patients. It seems that bone degradation is accelerated during long-term high dose thyroxine therapy. The normal regulation of bone metabolism is altered during long^term high dose thyroxine treatment, since the effects of age and physical activity were not seen in patients. As patients received thyroid hormone treatment, obvious differences were found in thyrotropin and thyroid hormone Status between the patients and controls. Although bone degradation seems to be accelerated in the patient group (free thyroid hormone concentrations were higher and thyrotropin concentrations were lower than in the controls), these hormone concentrations were not able to predict the level of the serum marker of bone degradation within the patient group in the present study. The age differences between the male patients and controls had no major effect on the results of the present study, äs age was included äs a covariate in the statistical analyses. In conclusion, long-term suppressive thyroxine treatment increases a serum marker öf bone degradation in men, and in premenopäüsal and postmenopausal women. Differentiäted thyroid cancer is generally diagnosed in young people and the patients may receive high-dose thyroxine treatment for decades. Problems due to side effects, such äs accelerated bone degradation, may arise gradually. Serum thyrotropin or free thyroid hormone concentrations were not reliable indicators of the level of the serum marker of bone degradation within the patient group. Thyroid hormones and thyrotropin suppression are essential for thyroid carcinoma patients. Therefore, longitudinal studies are needed in order to defme the optimal amount of thyroxine and the degree of thyrotropin suppression, taking into account the side effects of the treatment.
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